The results of an international clinical trial led by Michael Birrer, M.D., Ph.D., director of the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences (UAMS), on the use of a novel bispecific antibody for women with recurrent or metastatic cervical cancer were published today in JAMA Oncology.
